| Catalyst | Drug/Treatment | Stage | Probability of Approval | Description | Drug Type | Therapeutic Area | Source |
|---|---|---|---|---|---|---|---|
PDUFA 2026 | Phase 3 | -% | FDA review of the new drug application for the treatment of example condition. Read More | Small Molecule | Oncology | ||
PDUFA 2026 | Phase 3 | -% | FDA review of the new drug application for the treatment of example condition. Read More | Small Molecule | Oncology | ||
PDUFA 2026 | Phase 3 | -% | FDA review of the new drug application for the treatment of example condition. Read More | Small Molecule | Oncology |
Recent Updates
Recently added Catalysts
Arcellx, Inc.
$115.07
+0.03 (+0.03%)
Last traded Apr 27, 2026. This price is not current.
D 30Pipeline Score Richly Valued Biotech · Clinical
Market Cap
6.73 B
EPS
-4.05
P/E Ratio
-
Value Trade
1.85 B
0.01 %
Week
0.39 %
1 Month
68.26 %
3 Month
31.98 %
6 Month
505.63 %
5 Year
505.63 %
All Time
Cash Data
Cash Position
-
Monthly Burn
-
Runway
-
Overview
Volume
16.12 M
52 Week Range
47.86 - 115.13
% held by Insiders
22.44 %
% held by Institutions
74.14 %
Enterprise Value
6.33 B
Total Shares
58.46 M
Short %
4.31 %
Float Shares
41.80 M
Company Description
locked
Upcoming Catalyst
Past FDA Catalysts & PDUFA Decisions
| Date | Drug | Catalyst | Stage | Outcome | Reaction | Event Move % | Best Trade % |
|---|---|---|---|---|---|---|---|
2025-12-31 | Anito-cel (CART-ddBCMA) | BLA Filing | BLA | delayed | – | – | – |
2025-12-31 | Anito-cel (CART-ddBCMA) | BLA Filing | BLA | delayed | – | – | – |
2025-12-31 | Anito-cel (CART-ddBCMA) | BLA Filing | BLA | delayed | – | – | – |
Drug Pipeline Intelligence
D30
Pipeline Score $295M
Pipeline ValueRichly Valued
Valuation Signal2
Drugs Scored0.2x
rNPV / MCap Top 38%
Small Cap (rank 579 of 933)
Percentile RankArcellx, Inc. faces pipeline headwinds (30/100), with $475M risk-adjusted pipeline value, led by anito-cel in Muscular Diseases (Phase 1).
Showing 1 of 1 assets
| Drug | Indication | Phase | NCT ID | PTRS | rNPV | Status | Enrollment | Velocity | Design | Completion | ML Signal | Last Change |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| anito-cel Monoclonal antibody | Muscular Diseases | Phase 1 | NCT06626919 | 18% | $374M | RECRUITING | 30 | STALLED | D (21) | Apr 1, 2028 | MODERATE_RISK | Feb 25, 2026 |
Clinical Trial Results
| Drug Name | Indications | Phase | Date | Trial Results Summary | Title | Source |
|---|---|---|---|---|---|---|
anito-cel | relapsed and/or refractory multiple myeloma | Phase 2 | 2025-05-14 | ORR: 97%; CR/s CR: 68%; VGPR: 85%; MRD negativity: 93.3%; 6 month PFS: 91.9%; 6 month OS: 96.6%; 12 month PFS: 78.8%; 12 month OS: 95.2% Read More | Arcellx Announces New Positive Data for Its iMMagine-1 Study in Patients with Relapsed and/or Refractory Multiple Myeloma Results from all 117 patients dosed in the pivotal Phase 2 iMMagine-1 study of anito-cel demonstra Read More | |
anito-cel | relapsed and/or refractory multiple myeloma | Phase 2 | 2025-05-14 | ORR: 97%; CR/s CR: 68%; VGPR: 85%; MRD negativity: 93.3%; 6 month PFS: 91.9%; 6 month OS: 96.6%; 12 month PFS: 78.8%; 12 month OS: 95.2% Read More | Arcellx Announces New Positive Data for Its iMMagine-1 Study in Patients with Relapsed and/or Refractory Multiple Myeloma Results from all 117 patients dosed in the pivotal Phase 2 iMMagine-1 study of anito-cel demonstra Read More | |
anito-cel | relapsed and/or refractory multiple myeloma | Phase 2 | 2025-05-14 | ORR: 97%; CR/s CR: 68%; VGPR: 85%; MRD negativity: 93.3%; 6 month PFS: 91.9%; 6 month OS: 96.6%; 12 month PFS: 78.8%; 12 month OS: 95.2% Read More | Arcellx Announces New Positive Data for Its iMMagine-1 Study in Patients with Relapsed and/or Refractory Multiple Myeloma Results from all 117 patients dosed in the pivotal Phase 2 iMMagine-1 study of anito-cel demonstra Read More |
Inside Trades
YEARLY INSIDER TRANSACTIONS
Sector Avg.
INSIDERS
SOLDINSIDERS
BOUGHT
SOLDINSIDERS
BOUGHT
POSITIVE SENTIMENT Based on 22 Insiders Transactions
Hedge Funds
Shares Held
HEDGE FUNDS
SOLDHEDGE FUNDS
BOUGHT
SOLDHEDGE FUNDS
BOUGHT
POSITIVE SENTIMENT Based on 27 hedge funds in the last quarter
18 buying (3 new)·9 selling (1 exited)·2 unchanged
Hedge Funds invested in ACLX
| HedgeFund Name ( 3 ) | % of Portfolio | Current MV - | Shares Owned - | Activity Avg Price $0 |
|---|---|---|---|---|
Example Capital Management | 2.5 % | 15.00 M | 250.00 K | |
Example Capital Management | 2.5 % | 15.00 M | 250.00 K | |
Example Capital Management | 2.5 % | 15.00 M | 250.00 K |
ACLX Institutional Ownership Trends
Current Insider %
5.20%
—+0.00%
Current Institutional %
62.40%
—+0.00%
Total Ownership
67.60%
Insider + Institutional
Data Points
1
1 Ticker(s)
Option Chain Statistics
| Expiration | Volume | Open Interest | Implied Volatility Calls | Implied Volatility Puts | ||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Calls | Puts | Put-Call Ratio | Calls | Puts | Put-Call Ratio | IV | OiWaIv | VWaIv | IV | OiWaIv | VWaIv | |
Option Chain
| Calls | Strike | Puts | ||||
|---|---|---|---|---|---|---|
| Last Price | Volume | Open Interest | Last Price | Volume | Open Interest | |
| No data available | ||||||
Open interest
Today's Open Interest
1.00 M
Put-Call Ratio
1.1
Put Open Interest
480.00 K
Call Open Interest
520.00 K
Open Interest Avg (30-day)
900,000
Today vs Open Interest Avg (30-day)
11.11%
Option Volume
Today's Volume
750.00 K
Put-Call Ratio
0.95
Put Volume
360.00 K
Call Volume
390.00 K
Volume Avg (30-day)
800,000
Today vs Volume Avg (30-day)
-6.25%
Company News
Competitive Position
How ACLX ranks across every disease it competes inCompetitive Position is a premium feature
See how ACLX ranks against every competitor across each disease it develops in: phase, best drug, trials and likelihood of approval.
Start free trial